Epidiolex Approval Suggests the Way Forward for Marijuana-Derived Products
Update Magazine | October/November 2018
Digital Health – FDA’s Approach Will Continue to Evolve
Update Magazine | October/November 2018
Case Study: Jazz Pharmaceuticals v. Amneal Pharmaceuticals
Update Magazine | October/November 2018
Student Corner: Right to Try Act: Is it the Answer for Terminally Ill Patients?
Update Magazine | October/November 2018
Global Focus: Clinical Trials in India
Update Magazine | October/November 2018
Organs on a Chip! FDA’s Predictive Toxicology Roadmap
Update Magazine | October/November 2018
Facilitating Competition and Innovation Isn’t Easy: FDA’s Latest Hearing On Biologics
Update Magazine Extra
Real World Evidence: Implications and Challenges for Medical Product Communications in an Evolving Regulatory Landscape GalleryReal World Evidence: Implications and Challenges for Medical Product Communications in an Evolving Regulatory Landscape
Archived Publication, Drugs, Medical Devices, Biologics, Publications, Update August/September 2018, Update Magazine
Real World Evidence: Implications and Challenges for Medical Product Communications in an Evolving Regulatory Landscape
Update Magazine | August/September 2018
FDA’s Historical Use of “Real World Evidence”
Update Magazine | August/September 2018
For FDA, Addressing Drug Pricing Is a Matter of Doing Its Job Better
Update Magazine | August/September 2018
